Rhythm Pharmaceuticals, Inc. also files under SRYTM; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Meeker David P | President and CEO, Director | Sell(S) | 31K | $102.35 | $3.1M |
| Sep 14, 2026 | Meeker David P | President and CEO, Director | Option exercise(M) | 50K | $6.05 | $303K |
| Sep 14, 2026 | Meeker David P | President and CEO, Director | Sell(S) | 2K | $105.19 | $242K |
| Sep 14, 2026 | Meeker David P | President and CEO, Director | Sell(S) | 9K | $103.43 | $900K |
| Sep 14, 2026 | Meeker David P | President and CEO, Director | Option exercise(M) | 50K | — | $0 |
| Sep 14, 2026 | Meeker David P | President and CEO, Director | Sell(S) | 2K | $104.55 | $190K |
| Sep 14, 2026 | Meeker David P | President and CEO, Director | Sell(S) | 6K | $101.75 | $655K |
| Aug 31, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 23K | $104.59 | $2.4M |
| Aug 31, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 12K | $105.37 | $1.2M |
| Aug 31, 2026 | Smith Hunter C | Chief Financial Officer | Option exercise(M) | 57K | — | $0 |
| Aug 31, 2026 | Smith Hunter C | Chief Financial Officer | Option exercise(M) | 57K | $25.79 | $1.5M |
| Aug 31, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 28K | $106.20 | $3.0M |
| Aug 17, 2026 | Joshi Manher | Chief Medical Officer | Grant(A) | 25K | — | $0 |
| Aug 17, 2026 | Joshi Manher | Chief Medical Officer | Grant(A) | 50K | — | $0 |
| Aug 13, 2026 | Lee Jennifer Kayden | EVP, Head of North America | Option exercise(M) | 22K | — | $0 |
| Aug 13, 2026 | Lee Jennifer Kayden | EVP, Head of North America | Option exercise(M) | 22K | $6.80 | $147K |
| Aug 13, 2026 | Lee Jennifer Kayden | EVP, Head of North America | Sell(S) | 76K | $117.38 | $8.9M |
| Aug 13, 2026 | Garfield Alastair | Chief Scientific Officer | Sell(S) | 2K | $116.11 | $233K |
| Aug 13, 2026 | Lee Jennifer Kayden | EVP, Head of North America | Option exercise(M) | 35K | $24.29 | $850K |
| Aug 13, 2026 | Lee Jennifer Kayden | EVP, Head of North America | Option exercise(M) | 35K | — | $0 |
| Aug 13, 2026 | Garfield Alastair | Chief Scientific Officer | Sell(S) | 3K | $118.28 | $402K |
| Aug 13, 2026 | Garfield Alastair | Chief Scientific Officer | Sell(S) | 800 | $119.17 | $95K |
| Aug 13, 2026 | Garfield Alastair | Chief Scientific Officer | Sell(S) | 2K | $117.08 | $182K |
| Aug 13, 2026 | Shulman Joseph | Chief Technical Officer | Sell(S) | 5K | $119.75 | $608K |
| Aug 13, 2026 | Shulman Joseph | Chief Technical Officer | Option exercise(M) | 2K | $6.80 | $14K |
| Aug 13, 2026 | Shulman Joseph | Chief Technical Officer | Option exercise(M) | 2K | — | $0 |
| Aug 12, 2026 | Mazabraud Yann | EVP, Head of International | Sell(S) | 2K | $111.80 | $257K |
| Aug 12, 2026 | Mazabraud Yann | EVP, Head of International | Sell(S) | 1K | $112.86 | $113K |
| Aug 12, 2026 | Mazabraud Yann | EVP, Head of International | Sell(S) | 4K | $114.70 | $413K |
| Aug 12, 2026 | Mazabraud Yann | EVP, Head of International | Option exercise(M) | 47K | $6.80 | $317K |
| Aug 12, 2026 | Mazabraud Yann | EVP, Head of International | Option exercise(M) | 47K | — | $0 |
| Aug 12, 2026 | Mazabraud Yann | EVP, Head of International | Sell(S) | 15K | $115.43 | $1.7M |
| Aug 12, 2026 | Mazabraud Yann | EVP, Head of International | Sell(S) | 18K | $116.49 | $2.1M |
| Aug 12, 2026 | Mazabraud Yann | EVP, Head of International | Sell(S) | 17K | $117.47 | $2.0M |
| Jul 1, 2026 | Garfield Alastair | Chief Scientific Officer | Option exercise(M) | 4K | — | $0 |
| Jul 1, 2026 | Garfield Alastair | Chief Scientific Officer | Tax withholding(F) | 2K | $110.41 | $237K |
| Jul 1, 2026 | Garfield Alastair | Chief Scientific Officer | Option exercise(M) | 4K | — | — |
| Jun 24, 2026 | Jean Christophe | Director | Grant(A) | 2K | — | $0 |
| Jun 24, 2026 | Arbuckle Stuart A | Director | Grant(A) | 4K | — | $0 |
| Jun 24, 2026 | Tetrault Lynn A. | Director | Grant(A) | 4K | — | $0 |
| Jun 24, 2026 | Arbuckle Stuart A | Director | Grant(A) | 2K | — | $0 |
| Jun 24, 2026 | Tetrault Lynn A. | Director | Grant(A) | 2K | — | $0 |
| Jun 24, 2026 | McGirr David W J | Director | Grant(A) | 2K | — | $0 |
| Jun 24, 2026 | McGirr David W J | Director | Grant(A) | 4K | — | $0 |
| Jun 24, 2026 | Jean Christophe | Director | Grant(A) | 4K | — | $0 |
| Jun 24, 2026 | Good Jennifer L | Director | Grant(A) | 2K | — | $0 |
| Jun 24, 2026 | Good Jennifer L | Director | Grant(A) | 4K | — | $0 |
| Jun 23, 2026 | Arbuckle Stuart A | Director | Option exercise(M) | 5K | — | $0 |
| Jun 23, 2026 | Jean Christophe | Director | Option exercise(M) | 5K | — | — |
| Jun 23, 2026 | Arbuckle Stuart A | Director | Option exercise(M) | 5K | — | — |
| Jun 23, 2026 | Tetrault Lynn A. | Director | Option exercise(M) | 5K | — | $0 |
| Jun 23, 2026 | Tetrault Lynn A. | Director | Option exercise(M) | 5K | — | — |
| Jun 23, 2026 | McGirr David W J | Director | Option exercise(M) | 5K | — | — |
| Jun 23, 2026 | Good Jennifer L | Director | Option exercise(M) | 5K | — | — |
| Jun 23, 2026 | Good Jennifer L | Director | Option exercise(M) | 5K | — | $0 |
| Jun 23, 2026 | Jean Christophe | Director | Option exercise(M) | 5K | — | $0 |
| Jun 23, 2026 | McGirr David W J | Director | Option exercise(M) | 5K | — | $0 |
| Jun 22, 2026 | Tetrault Lynn A. | Director | Sell(S) | 37K | $100.32 | $3.7M |
| Jun 22, 2026 | Tetrault Lynn A. | Director | Option exercise(M) | 37K | $28.27 | $1.0M |
| Jun 22, 2026 | Tetrault Lynn A. | Director | Option exercise(M) | 37K | — | $0 |
| May 18, 2026 | Smith Hunter C | Chief Financial Officer | Option exercise(M) | 3K | $17.87 | $54K |
| May 18, 2026 | Smith Hunter C | Chief Financial Officer | Option exercise(M) | 3K | — | $0 |
| May 15, 2026 | German Christopher Paul | Corporate Controller & CAO | Option exercise(M) | 1K | — | $0 |
| May 15, 2026 | German Christopher Paul | Corporate Controller & CAO | Option exercise(M) | 1K | — | $0 |
| May 15, 2026 | German Christopher Paul | Corporate Controller & CAO | Option exercise(M) | 2K | — | $0 |
| May 15, 2026 | German Christopher Paul | Corporate Controller & CAO | Sell(S) | 5K | $92.21 | $428K |
| May 15, 2026 | German Christopher Paul | Corporate Controller & CAO | Option exercise(M) | 2K | $56.69 | $96K |
| May 15, 2026 | German Christopher Paul | Corporate Controller & CAO | Option exercise(M) | 1K | $49.23 | $66K |
| May 15, 2026 | German Christopher Paul | Corporate Controller & CAO | Option exercise(M) | 1K | $17.97 | $25K |
| Apr 1, 2026 | Popovits Kimberly J | Director | Grant(A) | 10K | — | $0 |
| Apr 1, 2026 | Popovits Kimberly J | Director | Grant(A) | 7K | — | $0 |
| Apr 1, 2026 | Mazabraud Yann | EVP, Head of International | Option exercise(M) | 10K | — | $0 |
| Apr 1, 2026 | Mazabraud Yann | EVP, Head of International | Option exercise(M) | 3K | — | $0 |
| Apr 1, 2026 | Mazabraud Yann | EVP, Head of International | Option exercise(M) | 13K | — | — |
| Mar 12, 2026 | Mathers Edward T | Director | Other(J) | 4K | — | $0 |
| Mar 4, 2026 | German Christopher Paul | Corporate Controller & CAO | Option exercise(M) | 2K | — | $0 |
| Mar 4, 2026 | German Christopher Paul | Corporate Controller & CAO | Sell(S) | 6K | $89.56 | $503K |
| Mar 4, 2026 | German Christopher Paul | Corporate Controller & CAO | Option exercise(M) | 2K | $17.97 | $27K |
| Mar 2, 2026 | Mathers Edward T | Director | Other(J) | 4K | — | $0 |
| Mar 2, 2026 | Mazabraud Yann | EVP, Head of International | Grant(A) | 35K | — | $0 |
| Mar 2, 2026 | Smith Hunter C | Chief Financial Officer | Option exercise(M) | 6K | — | $0 |
| Mar 2, 2026 | Smith Hunter C | Chief Financial Officer | Option exercise(M) | 6K | $6.80 | $41K |
| Mar 1, 2026 | German Christopher Paul | Corporate Controller & CAO | Option exercise(M) | 1K | — | $0 |
| Mar 1, 2026 | German Christopher Paul | Corporate Controller & CAO | Tax withholding(F) | 342 | $94.94 | $32K |
| Mar 1, 2026 | German Christopher Paul | Corporate Controller & CAO | Option exercise(M) | 1K | — | — |
| Feb 19, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 585 | $103.28 | $60K |
| Feb 19, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 800 | $102.10 | $82K |
| Feb 19, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 2K | $100.92 | $171K |
| Feb 19, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 1K | $100.27 | $131K |
| Feb 17, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 200 | $103.84 | $21K |
| Feb 17, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 1K | $99.42 | $119K |
| Feb 17, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 1K | $103.00 | $110K |
| Feb 17, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 900 | $101.70 | $92K |
| Feb 17, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 200 | $100.52 | $20K |
| Feb 14, 2026 | Mazabraud Yann | EVP, Head of International | Option exercise(M) | 10K | — | $0 |
| Feb 14, 2026 | Mazabraud Yann | EVP, Head of International | Option exercise(M) | 10K | — | — |
| Feb 12, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 292 | $96.26 | $28K |
| Feb 12, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 400 | $97.67 | $39K |
| Feb 12, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 800 | $98.99 | $79K |
| Feb 12, 2026 | Smith Hunter C | Chief Financial Officer | Sell(S) | 100 | $100.10 | $10K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Rhythm Pharmaceuticals, Inc., SEC CIK 0001649904. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under RYTM and shows every filing by that issuer (also filed as SRYTM).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-15. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for RYTM